| 前收盘价格 | 55.45 |
| 收盘价格 | 55.47 |
| 成交量 | 115,781 |
| 平均成交量 (3个月) | 660,879 |
| 市值 | 3,037,459,200 |
| 预期市盈率 (P/E Forward) | 12.56 |
| 价格/销量 (P/S) | 2.14 |
| 股市价格/股市净资产 (P/B) | 2.49 |
| 52周波幅 | |
| 利润日期 | 29 Oct 2025 |
| 营业毛利率 | -17.42% |
| 营业利益率 (TTM) | 15.54% |
| 稀释每股收益 (EPS TTM) | -4.07 |
| 季度收入增长率 (YOY) | 7.40% |
| 季度盈利增长率 (YOY) | 242.10% |
| 总债务/股东权益 (D/E MRQ) | 65.54% |
| 流动比率 (MRQ) | 1.58 |
| 营业现金流 (OCF TTM) | 197.02 M |
| 杠杆自由现金流 (LFCF TTM) | 782.12 M |
| 资产报酬率 (ROA TTM) | 4.55% |
| 股东权益报酬率 (ROE TTM) | -19.70% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Medical Devices (US) | 混合的 | 看跌 |
| Medical Devices (全球的) | 混合的 | 看跌 | |
| 股票 | LivaNova PLC | 看涨 | 看跌 |
AIStockmoo 评分
0.3
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | -1.5 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.25 |
|
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world. |
|
| 部门 | Healthcare |
| 行业 | Medical Devices |
| 投资方式 | Small Core |
| 内部持股比例 | 0.38% |
| 机构持股比例 | 102.95% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 64.00 (Needham, 15.05%) | 购买 |
| 中 | 61.00 (9.65%) | |
| 低 | 58.00 (Barclays, 4.26%) | 保留 |
| 平均值 | 61.00 (9.65%) | |
| 总计 | 1 购买, 1 保留 | |
| 平均价格@调整类型 | 54.73 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 03 Sep 2025 | 64.00 (15.05%) | 购买 | 56.59 |
| Barclays | 21 Aug 2025 | 58.00 (4.26%) | 保留 | 52.86 |
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 04 Sep 2025 | 公告 | LivaNova Appoints Donald Zurbay as a New Director |
| 25 Aug 2025 | 公告 | LivaNova to Host Investor Day on November 12, 2025 |
| 22 Aug 2025 | 公告 | LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September |
| 18 Aug 2025 | 公告 | LivaNova Launches Essenz Perfusion System in China |
| 06 Aug 2025 | 公告 | LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance |
| 09 Jul 2025 | 公告 | LivaNova to Announce Second-Quarter 2025 Results |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合